Free tools Windows power users keep installed
One-click scans. No signup required.
The FDA approved Zanvastro (zilganersen) on September 3, 2026, as the first treatment for Alexander disease, for pediatric and adult patients. The prescription injection is designed to reduce production of GFAP, the protein whose abnormal accumulation is associated with the disease. In a controlled study, the drug slowed the decline in walking speed compared with control; it did not mean every patient improved or that the disease was cured.
What Alexander disease is—and what the approval changes
Alexander disease is an ultra-rare, progressive neurological disorder associated with pathogenic variants in the GFAP gene. The gene provides instructions for making glial fibrillary acidic protein (GFAP). Abnormal GFAP can accumulate in astrocytes, cells that support the nervous system, and contribute to damage over time. Possible effects include seizures, loss of developmental milestones, difficulty walking, muscle weakness and increased pressure in the brain, according to the FDA.
As an Amazon Associate I earn from qualifying purchases.
The FDA calls Zanvastro the first approved treatment for the disease and the first therapy to target the underlying protein buildup. Before this approval, care was supportive, aimed at managing symptoms rather than reducing GFAP production. The FDA describes the disease as affecting fewer than 1 in a million people; Ionis Pharmaceuticals gives a separate estimate of approximately 1 in 1 to 3 million worldwide. Those estimates come from different organizations and are not directly reconciled.
Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchPC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11How Zanvastro is intended to work and how it is given
Zanvastro is an antisense oligonucleotide directed at GFAP. Its intended action is to reduce production of the protein before abnormal GFAP can accumulate. That mechanism explains the treatment’s rationale; clinical benefit was assessed through measured outcomes over the study period, not by assuming that lowering GFAP necessarily improves every symptom.
#1 Best Overall
A trained healthcare professional injects the medicine into the spinal canal every three months. In the main study, the 50 mg regimen was given every 12 weeks. It is not a self-administered treatment. The current U.S. prescribing information provides the detailed dosing and safety information.
What the clinical study found
Participants and study design
The FDA-approved label describes Study 1, which included a randomized, controlled Main Study of 49 participants aged 2 to 65, plus an open-label substudy of four children younger than 2. Participants had Alexander disease confirmed through clinical features, brain MRI and a pathogenic GFAP variant. In the Main Study, the double-blind period ran through Week 61; participants aged 2 and older entered 25 mg or 50 mg ascending-dose cohorts and were randomized 2:1 to Zanvastro or control.
Walking-speed result in patients aged 5 and older
For the primary analysis in the 50 mg group among patients aged 5 and older who had walking difficulty at the start, gait speed on the 10-meter walk test changed by -2.1% with Zanvastro and -35.4% with control at Week 61. The adjusted between-group difference in change was 33.3 percentage points (95% confidence interval 1.44 to 65.25; p=0.041), according to the prescribing information. The comparison indicates less decline in the treated group over the study period; it is not a 33.3% absolute speed increase for every patient.
Quick wins for a faster PC:
Scan for outdated or missing drivers - takes under a minuteDriver Scan →Repair Windows errors before they cause bigger problemsFix Now →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Children aged 2 to 4
Walking speed was not considered a reliable measure of progress for this age group. The FDA says investigators instead used a broader motor assessment covering standing, walking, running and jumping; treated children improved on that measure while children in the control group declined. Ionis identifies the assessment as the Gross Motor Function Measure-88 and says secondary and exploratory outcomes reported by patients, caregivers and clinicians also favored treatment. That characterization of the additional outcomes is the manufacturer’s.
Rank #3
Children younger than 2
The under-2 evidence did not come from a concurrent controlled efficacy trial. The label supports use in this age group by drawing on the controlled study in older patients, pharmacokinetic analyses and modeling that predicted similar cerebrospinal fluid exposure after a 50 mg dose, and safety experience in four children younger than 2. The FDA says the evidence is constrained by the disease’s rarity and the absence of a concurrent control group for these children.
Known side effects and safety considerations
In the clinical trial, the most common adverse reactions in the 50 mg group and control group, respectively, were:
| Adverse reaction | Zanvastro 50 mg | Control |
|---|---|---|
| Vomiting | 50% | 29% |
| Back pain | 50% | 18% |
| Cough | 38% | 18% |
| Headache | 29% | 12% |
| Post-lumbar-puncture syndrome | 29% | 6% |
These are study rates, not estimates of how often the reactions occur in all patients receiving treatment. The FDA also warns that aseptic meningitis has been reported and advises patients and caregivers to contact the treating healthcare provider if symptoms consistent with meningitis develop.
The label also reports pleocytosis—an increased white blood cell count in cerebrospinal fluid—after the first two to four doses in 7 of 24 patients (29%) treated with 50 mg and 3 of 17 controls (18%) during the double-blind period, as well as in six additional patients treated during the open-label extension. One patient had a serious aseptic meningitis adverse reaction that recurred during the extension and required dose interruption and pretreatment. For individual treatment decisions, consult the current full label and the patient’s clinician.
Best Value
Why the announcement refers to more than 30 years of research
The “30 years” refers to the research history, not the length of the clinical trial. In an account published September 10, 2026, the University of Wisconsin–Madison traced the work of Albee Messing, VMD, PhD, and collaborators from investigations into GFAP through disease models and a treatment strategy using antisense oligonucleotides. The university credits Messing and Michael Brenner with identifying the genetic root cause in the late 1990s.
UW–Madison recounts that Messing’s group developed a GFAP-overexpressing mouse model and later rodent models, then worked with Tracy Hagemann and Ionis on antisense oligonucleotides intended to reduce GFAP. Positive rodent results led to the clinical trial, which began in summer 2021. Messing described the news to the university as “a wonderful and long-awaited day for the Alexander disease community.”
Regulatory designations and patient support
The FDA says Zanvastro received Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations, and that approval carries a Priority Review Voucher. These designations and the voucher are regulatory program details; they are not additional clinical outcome measures.
Do these 3 things before closing this tab:
1Fix the driver behind crashes, sound loss and screen glitches2Clear out junk files and repair common Windows errors3Scan for outdated or missing drivers - takes under a minuteIonis says its Every Step program offers education for patients and caregivers, a dedicated Patient Education Manager, help with insurance approval, affordability information and ongoing support. Availability and individual eligibility should be confirmed with the program and the treating care team.
What to take away from the evidence
The approval makes Zanvastro a new option intended to address GFAP production, rather than only provide supportive care. The clearest controlled result described in the label is a difference in gait-speed change for a defined group of patients aged 5 and older; evidence for younger children uses different measures, and use below age 2 relies partly on modeling and limited safety experience. The treatment’s benefits and risks should be considered with a clinician familiar with Alexander disease.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
